Pages that link to "Q27684091"
The following pages link to Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin (Q27684091):
Displaying 50 items.
- Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer (Q24617184) (← links)
- Targeting the mTOR kinase domain: the second generation of mTOR inhibitors (Q24622194) (← links)
- Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents (Q28067417) (← links)
- Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives (Q28071388) (← links)
- mTOR inhibitors in cancer therapy (Q28079129) (← links)
- Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent (Q28486289) (← links)
- Predicting mTOR inhibitors with a classifier using recursive partitioning and Naïve Bayesian approaches (Q28538732) (← links)
- Anticancer compound plumbagin and its molecular targets: a structural insight into the inhibitory mechanisms using computational approaches (Q28540187) (← links)
- Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines (Q28542662) (← links)
- Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines (Q28546221) (← links)
- Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K (Q29614757) (← links)
- Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development (Q33776641) (← links)
- Recent advances in the discovery of small molecule mTOR inhibitors (Q33852446) (← links)
- Small-molecule inhibitors of the PI3K signaling network (Q33883982) (← links)
- Blocking the mTOR pathway: a drug discovery perspective (Q34172699) (← links)
- The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases (Q34286572) (← links)
- mTOR kinase: a possible pharmacological target in the management of chronic pain (Q35035474) (← links)
- Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells (Q35079017) (← links)
- Discovery of a Potent Class of PI3Kα Inhibitors with Unique Binding Mode via Encoded Library Technology (ELT). (Q35640508) (← links)
- Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases. (Q35755996) (← links)
- Docking Studies on Isoform-Specific Inhibition of Phosphoinositide-3-Kinases (Q35781662) (← links)
- Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells (Q36311216) (← links)
- Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays (Q36432654) (← links)
- Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases (Q36503052) (← links)
- The effects of anticancer drugs TSA and GSK on spermatogenesis in male mice (Q36595148) (← links)
- Nimbolide, a neem limonoid inhibits Phosphatidyl Inositol-3 Kinase to activate Glycogen Synthase Kinase-3β in a hamster model of oral oncogenesis (Q36606111) (← links)
- Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells (Q36772192) (← links)
- Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair (Q37041046) (← links)
- Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF (Q37156395) (← links)
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. (Q37350230) (← links)
- Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). (Q37565213) (← links)
- Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy (Q37587308) (← links)
- Endothelin-1 suppresses insulin-stimulated Akt phosphorylation and glucose uptake via GPCR kinase 2 in skeletal muscle cells (Q37686147) (← links)
- Current and future directions in mammalian target of rapamycin inhibitors development (Q37836904) (← links)
- Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs (Q37872655) (← links)
- Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review (Q37876907) (← links)
- Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors (Q37886009) (← links)
- Pyrazolo[3,4-b]pyridine kinase inhibitors: a patent review (2008--present). (Q38071651) (← links)
- Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment (Q38106130) (← links)
- Analysis of phosphoinositide 3-kinase inhibitors by bottom-up electron-transfer dissociation hydrogen/deuterium exchange mass spectrometry. (Q38288444) (← links)
- Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review (Q38515841) (← links)
- Dissecting fibrosis: therapeutic insights from the small-molecule toolbox (Q38580461) (← links)
- Autophagy inhibitors (Q38666985) (← links)
- Benzenesulphonamide inhibitors of the cytolytic protein perforin. (Q38720085) (← links)
- Signaling pathways as therapeutic targets in biliary tract cancer. (Q38747573) (← links)
- Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications (Q38812037) (← links)
- Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway (Q39024437) (← links)
- Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. (Q39189263) (← links)
- Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner (Q39325158) (← links)
- Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer (Q39507521) (← links)